The effect of intravitreal bevacizumab in the treatment of Coats disease in children.
Jill Razor
JR
Wells
George Baker
GB
Hubbard
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002675:Child, Preschool; D003937:Diagnosis, Differential; D004333:Drug Administration Routes; D015353:Eye Enucleation; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D019572:Retinal Neoplasms / Q000175:diagnosis* / Q000601:surgery; D058456:Retinal Telangiectasis / Q000175:diagnosis* / Q000188:drug therapy; D012171:Retinal Vessels / Q000187:drug effects / Q000473:pathology*; D012175:Retinoblastoma / Q000175:diagnosis* / Q000601:surgery
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab